Literature DB >> 20709108

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines.

Michael A Whitt1.   

Abstract

Vesicular stomatitis virus (VSV) is a prototypic enveloped animal virus that has been used extensively to study virus entry, replication and assembly due to its broad host range and robust replication properties in a wide variety of mammalian and insect cells. Studies on VSV assembly led to the creation of a recombinant VSV in which the glycoprotein (G) gene was deleted. This recombinant (rVSV-ΔG) has been used to produce VSV pseudotypes containing the envelope glycoproteins of heterologous viruses, including viruses that require high-level biocontainment; however, because the infectivity of rVSV-ΔG pseudotypes is restricted to a single round of replication the analysis can be performed using biosafety level 2 (BSL-2) containment. As such, rVSV-ΔG pseudotypes have facilitated the analysis of virus entry for numerous viral pathogens without the need for specialized containment facilities. The pseudotypes also provide a robust platform to screen libraries for entry inhibitors and to evaluate the neutralizing antibody responses following vaccination. This manuscript describes methods to produce and titer rVSV-ΔG pseudotypes. Procedures to generate rVSV-ΔG stocks and to quantify virus infectivity are also described. These protocols should allow any laboratory knowledgeable in general virological and cell culture techniques to produce successfully replication-restricted rVSV-ΔG pseudotypes for subsequent analysis.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20709108      PMCID: PMC2956192          DOI: 10.1016/j.jviromet.2010.08.006

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  40 in total

1.  N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry.

Authors:  M Perez; M Watanabe; M A Whitt; J C de la Torre
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  The interaction of antibody with the major surface glycoprotein of vesicular stomatitis virus. I. Analysis of neutralizing epitopes with monoclonal antibodies.

Authors:  L Lefrancois; D S Lyles
Journal:  Virology       Date:  1982-08       Impact factor: 3.616

3.  Pseudotypes of avian sarcoma viruses with the envelope properties of vesicular stomatitis virus.

Authors:  R A Weiss; D Boettiger; H M Murphy
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

4.  Efficient selection for high-expression transfectants with a novel eukaryotic vector.

Authors:  H Niwa; K Yamamura; J Miyazaki
Journal:  Gene       Date:  1991-12-15       Impact factor: 3.688

5.  Phenotypic mixing of vesicular stomatitis virus with fowl plague virus.

Authors:  J Závada; M Rosenbergová
Journal:  Acta Virol       Date:  1972-03       Impact factor: 1.162

6.  A kinetic analysis of the synthesis in BHK 21 cells of RNAs specific for Semliki Forest virus.

Authors:  L Kaariainen; P J Gomatos
Journal:  J Gen Virol       Date:  1969-09       Impact factor: 3.891

7.  Analysis of the molecules involved in human T-cell leukaemia virus type 1 entry by a vesicular stomatitis virus pseudotype bearing its envelope glycoproteins.

Authors:  Kazu Okuma; Yoshiharu Matsuura; Hironobu Tatsuo; Yoshio Inagaki; Minoru Nakamura; Naoki Yamamoto; Yusuke Yanagi
Journal:  J Gen Virol       Date:  2001-04       Impact factor: 3.891

8.  Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.

Authors:  H Ito; S Watanabe; A Sanchez; M A Whitt; Y Kawaoka
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

9.  A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.

Authors:  Jean Publicover; Elizabeth Ramsburg; John K Rose
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

10.  Replication and amplification of novel vesicular stomatitis virus minigenomes encoding viral structural proteins.

Authors:  E A Stillman; J K Rose; M A Whitt
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more
  142 in total

1.  Anterograde or Retrograde Transsynaptic Circuit Tracing in Vertebrates with Vesicular Stomatitis Virus Vectors.

Authors:  Kevin T Beier; Nathan A Mundell; Y Albert Pan; Constance L Cepko
Journal:  Curr Protoc Neurosci       Date:  2016-01-04

2.  Use of replication restricted recombinant vesicular stomatitis virus vectors for detection of antigen-specific T cells.

Authors:  Nelson B Moseley; Oskar Laur; Chris C Ibegbu; Gilbert D Loria; Gini Ikwuenzunma; Himangi R Jayakar; Michael A Whitt; John D Altman
Journal:  J Immunol Methods       Date:  2011-10-08       Impact factor: 2.303

3.  Coronavirus and influenza virus proteolytic priming takes place in tetraspanin-enriched membrane microdomains.

Authors:  James T Earnest; Michael P Hantak; Jung-Eun Park; Tom Gallagher
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

4.  Antagonistic effects of cellular poly(C) binding proteins on vesicular stomatitis virus gene expression.

Authors:  Phat X Dinh; Lalit K Beura; Debasis Panda; Anshuman Das; Asit K Pattnaik
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

5.  In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus.

Authors:  Jian Ma; Ruifeng Chen; Weijin Huang; Jianhui Nie; Qiang Liu; Youchun Wang; Xiaoming Yang
Journal:  Hum Vaccin Immunother       Date:  2019-06-20       Impact factor: 3.452

6.  Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting.

Authors:  Jean K Millet; Tiffany Tang; Lakshmi Nathan; Javier A Jaimes; Hung-Lun Hsu; Susan Daniel; Gary R Whittaker
Journal:  J Vis Exp       Date:  2019-03-01       Impact factor: 1.355

7.  Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.

Authors:  Valérie Janelle; Frédérick Brassard; Pascal Lapierre; Alain Lamarre; Laurent Poliquin
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

8.  Digital sensing and sizing of vesicular stomatitis virus pseudotypes in complex media: a model for Ebola and Marburg detection.

Authors:  George G Daaboul; Carlos A Lopez; Jyothsna Chinnala; Bennett B Goldberg; John H Connor; M Selim Ünlü
Journal:  ACS Nano       Date:  2014-06-04       Impact factor: 15.881

9.  Analysis of CD8+ T cell response during the 2013-2016 Ebola epidemic in West Africa.

Authors:  Saori Sakabe; Brian M Sullivan; Jessica N Hartnett; Refugio Robles-Sikisaka; Karthik Gangavarapu; Beatrice Cubitt; Brian C Ware; Dylan Kotliar; Luis M Branco; Augustine Goba; Mambu Momoh; John Demby Sandi; Lansana Kanneh; Donald S Grant; Robert F Garry; Kristian G Andersen; Juan Carlos de la Torre; Pardis C Sabeti; John S Schieffelin; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2018-07-23       Impact factor: 11.205

10.  Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection.

Authors:  Arlene Barlan; Jincun Zhao; Mayukh K Sarkar; Kun Li; Paul B McCray; Stanley Perlman; Tom Gallagher
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.